Literature DB >> 26783726

Relevance of microRNA-18a and microRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation.

Kazutoyo Morita1, Ken Shirabe1, Akinobu Taketomi1, Yuji Soejima1, Tomoharu Yoshizumi1, Hideaki Uchiyama1, Toru Ikegami1, Yo-Ichi Yamashita1, Keishi Sugimachi1, Norifumi Harimoto1, Shinji Itoh1, Tetsuo Ikeda1, Yoshihiko Maehara1.   

Abstract

There are few reports about recurrence-related microRNAs (miRNAs) after liver transplantation (LT) for hepatocellular carcinoma (HCC). The purpose of this study was to identify novel recurrence-related miRNAs after living donor liver transplantation (LDLT) for HCC. First, we performed microarray analyses of samples from a liver with primary HCC, a liver that was noncancerous, and a liver that had recurrence-metastasis from 3 patients with posttransplant recurrence. Then we selected miRNAs with consistently altered expression in both primary HCC and recurrence as potential candidates of recurrence-related miRNAs. Expression of the miRNAs in HCC and noncancerous livers was assessed in 70 HCC patients who underwent LDLT. The target genes regulated by the recurrence-related miRNAs were identified. MicroRNA-18a (miR-18a) expression was increased, and microRNA-199a-5p (miR-199a-5p) expression was decreased in both primary HCC and recurrence. Increased miR-18a expression correlated with high levels of tumor markers, large tumor size, and a high recurrence rate. Decreased miR-199a-5p expression correlated with high levels of tumor markers, portal venous invasion, and a high recurrence rate. In HCC cells, miR-18a regulated the expression of tumor necrosis factor alpha-induced protein 3 (TNFAIP3), and miR-199a-5p regulated the expression of hypoxia-inducible factor 1 alpha (HIF1A), vascular endothelial growth factor A (VEGFA), insulin-like growth factor 1 receptor, and insulin-like growth factor 2. In conclusion, increased miR-18a levels and decreased miR-199a-5p levels are relevant to HCC recurrence after LDLT. MiR-18a and miR-199a-5p could be novel therapeutic targets of recurrent HCC after LDLT. Liver Transplantation 22 665-676 2016 AASLD.
© 2016 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26783726     DOI: 10.1002/lt.24400

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  11 in total

Review 1.  Mitochondrial microRNA (MitomiRs) in cancer and complex mitochondrial diseases: current status and future perspectives.

Authors:  Paresh Kumar Purohit; Neeru Saini
Journal:  Cell Mol Life Sci       Date:  2020-10-21       Impact factor: 9.261

2.  Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis.

Authors:  Yue Zhang; Chao Wei; Cong-Cong Guo; Rong-Xiu Bi; Jin Xie; Dong-Hui Guan; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-09-14

3.  High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer.

Authors:  Xiaoxiao Xu; Shan Zhu; Zhaowu Tao; Shenglan Ye
Journal:  Cancer Med       Date:  2017-12-21       Impact factor: 4.452

4.  Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas.

Authors:  Francesco Vasuri; Silvia Fittipaldi; Vanessa De Pace; Laura Gramantieri; Valentina Bertuzzo; Matteo Cescon; Antonio D Pinna; Michelangelo Fiorentino; Antonia D'Errico; Matteo Ravaioli
Journal:  Oncotarget       Date:  2018-04-03

5.  Clinical significance of microRNA-449a in hepatocellular carcinoma with microarray data mining together with initial bioinformatics analysis.

Authors:  Xia Yang; Han-Lin Wang; Hai-Wei Liang; Liang Liang; Dong-Yue Wen; Rui Zhang; Gang Chen; Dan-Ming Wei
Journal:  Exp Ther Med       Date:  2018-02-05       Impact factor: 2.447

Review 6.  Biology of MiR-17-92 Cluster and Its Progress in Lung Cancer.

Authors:  Xinju Zhang; Yanli Li; Pengfei Qi; Zhongliang Ma
Journal:  Int J Med Sci       Date:  2018-09-07       Impact factor: 3.738

Review 7.  Role of microRNAs in the main molecular pathways of hepatocellular carcinoma.

Authors:  Francesco Vasuri; Michela Visani; Giorgia Acquaviva; Thomas Brand; Michelangelo Fiorentino; Annalisa Pession; Giovanni Tallini; Antonia D'Errico; Dario de Biase
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

8.  Prognostic value and prospective molecular mechanism of miR-100-5p in hepatocellular carcinoma: A comprehensive study based on 1,258 samples.

Authors:  Qing-Lin He; Shan-Yu Qin; Lin Tao; Hong-Jian Ning; Hai-Xing Jiang
Journal:  Oncol Lett       Date:  2019-10-04       Impact factor: 2.967

Review 9.  Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review.

Authors:  Taiji Tohyama; Katsunori Sakamoto; Kei Tamura; Taro Nakamura; Jota Watanabe; Hiroyuki Wakisaka; Yasutsugu Takada
Journal:  World J Surg Oncol       Date:  2020-05-28       Impact factor: 2.754

Review 10.  Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.

Authors:  Hitoshi Yoshiji; Sumiko Nagoshi; Takemi Akahane; Yoshinari Asaoka; Yoshiyuki Ueno; Koji Ogawa; Takumi Kawaguchi; Masayuki Kurosaki; Isao Sakaida; Masahito Shimizu; Makiko Taniai; Shuji Terai; Hiroki Nishikawa; Yoichi Hiasa; Hisashi Hidaka; Hiroto Miwa; Kazuaki Chayama; Nobuyuki Enomoto; Tooru Shimosegawa; Tetsuo Takehara; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-07-07       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.